Trade Ascendis Pharma A/S - ASND CFD

Trading Conditions

• Type: CFD
• Spread: 0.65
• Long position overnight funding adjustment: -0.02149%
• Short position overnight funding adjustment: -0.00074%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 0.1
• Margin: 50.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premium: 1%

Key Stats

• Prev. Close: 222.8
• Open: 222.45
• 1-Year Change: 34.11%
• Day's Range: 221.47 - 225.61

What is Ascendis Pharma A/S (ASND)?

Ascendis Pharma A/S is a biotechnology company focused on developing innovative therapies for rare endocrine diseases. The company utilizes proprietary TransCon technology to create long-acting prodrugs that aim to improve treatment efficacy and patient compliance. Its pipeline includes products targeting conditions such as growth hormone deficiency, hypoparathyroidism, and other hormonal disorders. Ascendis Pharma engages in research and development activities to advance its therapeutic candidates through clinical trials. The company collaborates with healthcare professionals and regulatory authorities to bring novel treatments to patients with unmet medical needs.

Ascendis Pharma A/S Stock Price Today: Live Overview

The price today is shaped by current session movements, with Smith & Nephew PLC trading at $222.27. It has fluctuated between $221.17 and $225.87 today, showing a daily change of -0.6822%.

FAQ: Ascendis Pharma A/S (ASND)

What is the current price of ASND stock?

The current price of Ascendis Pharma A/S is $222.27.

Does ASND pay dividends?

Ascendis Pharma A/S does not pay dividends.

Does ASND have a formal corporate presence or regional headquarters in the UAE?

Ascendis Pharma A/S operates in the UAE only through partners without a regional office.

What is ASND best known for?

Ascendis Pharma A/S is most famous for its development of long-acting prodrug therapies.

What assets are typically shown together with ASND?

Commonly shown alongside ASND: Amundi PEA MSCI USA ESG Selection UCITS ETF, UroGen Pharma Ltd., Bright Horizons Family Solutions Inc